CellaVision — Regulatory Filings 2014

Dec 11, 2014

CellaV mark Vision r ket receives its first t major o order fo or the ve eterinar ry

CellaVis market. the end few larg value of sion AB has . The order of this year ge customer f about 10 m received it supplies eq r. As the vet rs, an order million SEK ts first majo quipment t terinary ma r of this size K. or order to o multiple l arket is stil e should be a veterinar laboratorie ll relatively e seen as a o ry laborator es and will b y small and one-time ev ry chain in be delivere is characte vent. The or the US d before rized by rder has a

Addition conducte equippe nal sales to t ed in 2015. W d with Cella the customer With a posit aVision® DM r's remainin tive outcome M9600 Vet an ng laboratori e, the majori nd CellaVisio ies depend o ity of the cha on®1200 V on certain ev ain's laborat et. valuations th tories may b hat will be be

Since 20 company together and cats 012, CellaVis y has entere r have about . sion has deve ed the US ma t a hundred eloped syste arket which laboratories ems specific is character s having sign ally for the v rized by a few nificant sam veterinary m w large labo ple volumes market. Since oratory chain s, primarily f e then, the ns which from dogs

"We are Globally market a analysis outside N CellaVisi very please y, the market as in the US. of white an North Amer ion. d to have pa t is still relat We need re d red cells in rica will also artnered wit tively small elatively larg n the blood. consolidate th our first m since few co ge sample vo The long-te e to larger un major custom ountries hav olumes to cr rm trend, ho nits, "says Yv mer in veter ve a consolid eate interes owever, is th vonne Mårte inary medic dated laborat t in the digit hat laborato ensson, CEO cine. tory tal ries O of

CellaVisi veterina for huma primary where th key driv for exter markets referenc laborato ion DM9600 ary laborator an blood wit target grou he volume o er is CellaVi rnal devices , blood analy ce laboratori ories. CellaVi 0 Vet and DM ries. The pro th the capac p is the appr f samples is ision softwa to access te ysis for anim ies. Instead t ision sells th M1200 Vet r oducts are an city to analyz roximately 1 high and th re for remot est results an mals is perfo they are typ he product d eplaces a ma n adapted v ze blood fro 100 larger v he need for a te CellaVisio nd cell image ormed, but in pically perfor directly to en anual micro ersion of Ce m the most veterinary la an effective a on® Remote es. In Europ n most cases rmed in vete nd customer scope for bl llaVision's e common pe aboratories i analytical me e Review Sof e and in oth s they are no erinary clini rs. ood analysis existing instr ts, ie dog an n the US and ethod is gre ftware, whic er geograph ot consolida cs or hospit s in the ruments nd cat. The d Canada, at. One ch allows hic ted in tal

For furt ther inform mation, pleas se contact:

Yvonne M Phone: + Email: yv Mårtensson +46 708 33 7 vonne.marte , CEO, CellaV 77 82. ensson@cel Vision AB lavision.com m

About CellaVision

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2013 sales were SEK 180 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries/supportoffices in the USA, Canada, Japan and China. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.

This information was released for public disclosure on December 11, 2014 at 08.20 pm CET.